Lyra Therapeutics Key Executives
This section highlights Lyra Therapeutics's key executives, including their titles and compensation details.
Find Contacts at Lyra Therapeutics
(Showing 0 of )
Lyra Therapeutics Earnings
This section highlights Lyra Therapeutics's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
$0.15
Stock Price
$9.90M
Market Cap
87
Employees
Watertown, MA
Location
Financial Statements
Access annual & quarterly financial statements for Lyra Therapeutics, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $1.53M | $1.56M | $1.36M | $285.00K | $- |
| Cost of Revenue | $- | $- | $1.07M | $1.00M | $95.00K |
| Gross Profit | $1.53M | $1.56M | $296.00K | $-716.00K | $-95.00K |
| Gross Profit Ratio | 100.00% | 100.00% | 21.72% | -251.20% | 0.00% |
| Research and Development Expenses | $43.77M | $48.03M | $38.80M | $29.69M | $12.52M |
| General and Administrative Expenses | $18.50M | $19.06M | $17.56M | $14.21M | $9.69M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $18.50M | $19.06M | $17.56M | $14.21M | $9.69M |
| Other Expenses | $35.62M | $- | $1.32M | $- | $- |
| Operating Expenses | $97.88M | $68.68M | $56.35M | $43.90M | $22.21M |
| Cost and Expenses | $97.88M | $68.68M | $56.35M | $43.90M | $22.21M |
| Interest Income | $2.95M | $4.50M | $1.04M | $102.00K | $82.00K |
| Interest Expense | $- | $- | $524.00K | $- | $- |
| Depreciation and Amortization | $471.00K | $278.00K | $1.07M | $1.00M | $95.00K |
| EBITDA | $-60.26M | $-65.25M | $-53.92M | $-42.61M | $-22.11M |
| EBITDA Ratio | -3928.42% | -4188.06% | -3937.93% | -15303.51% | 0.00% |
| Operating Income | $-96.35M | $-67.12M | $-56.31M | $-43.62M | $-22.21M |
| Operating Income Ratio | -6280.83% | -4308.09% | -4131.03% | -15303.51% | 0.00% |
| Total Other Income Expenses Net | $2.95M | $4.50M | $1.04M | $102.00K | $82.00K |
| Income Before Tax | $-93.40M | $-62.62M | $-55.27M | $-43.51M | $-22.13M |
| Income Before Tax Ratio | -6088.40% | -4019.32% | -4054.66% | -15267.72% | 0.00% |
| Income Tax Expense | $39.00K | $59.00K | $13.00K | $-1.10M | $-82.00K |
| Net Income | $-93.44M | $-62.68M | $-55.28M | $-42.41M | $-22.05M |
| Net Income Ratio | -6090.94% | -4023.11% | -4055.61% | -14880.70% | 0.00% |
| EPS | $-1.43 | $-1.26 | $-1.83 | $-3.27 | $-2.57 |
| EPS Diluted | $-1.43 | $-1.26 | $-1.83 | $-3.27 | $-2.57 |
| Weighted Average Shares Outstanding | 65.11M | 49.80M | 30.24M | 12.99M | 8.59M |
| Weighted Average Shares Outstanding Diluted | 65.11M | 49.80M | 30.24M | 12.99M | 8.59M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $209.00K | $195.00K | $598.00K | $532.00K | $146.00K | $544.00K | $458.00K | $410.00K | $11.00K | $359.00K | $407.00K | $5.37M | $271.00K | $14.00K | $- | $- | $- | $- | $- | $- |
| Cost of Revenue | $- | $- | $13.26M | $136.00K | $85.00K | $12.37M | $10.80M | $284.00K | $222.00K | $- | $300.00K | $280.00K | $14.00K | $6.38M | $300.00K | $70.00K | $3.74M | $3.71M | $- | $- |
| Gross Profit | $209.00K | $195.00K | $-12.67M | $396.00K | $61.00K | $-11.82M | $-10.34M | $126.00K | $-211.00K | $359.00K | $107.00K | $5.09M | $257.00K | $-6.36M | $-300.00K | $-70.00K | $-3.74M | $-3.71M | $- | $- |
| Gross Profit Ratio | 100.00% | 100.00% | -2118.10% | 74.40% | 41.80% | -2173.50% | -2257.90% | 30.70% | -1918.20% | 100.00% | 26.30% | 94.80% | 94.80% | -45450.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $6.36M | $5.90M | $13.26M | $18.10M | $12.18M | $12.37M | $10.80M | $12.60M | $9.45M | $10.05M | $10.79M | $8.51M | $10.34M | $7.08M | $7.50M | $4.77M | $3.74M | $3.71M | $2.10M | $2.96M |
| General and Administrative Expenses | $3.61M | $3.93M | $5.14M | $5.82M | $4.36M | $5.00M | $4.57M | $5.13M | $4.40M | $5.14M | $4.13M | $3.89M | $3.57M | $4.02M | $3.56M | $3.06M | $3.31M | $2.65M | $2.44M | $1.28M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $3.61M | $3.93M | $5.14M | $5.82M | $4.36M | $5.00M | $4.57M | $5.13M | $4.40M | $5.14M | $4.13M | $3.89M | $3.57M | $4.02M | $3.56M | $3.06M | $3.31M | $2.65M | $2.44M | $1.28M |
| Other Expenses | $1.64M | $2.80M | $29.29M | $- | $- | $- | $1.59M | $- | $1.32M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Operating Expenses | $11.62M | $12.64M | $18.26M | $23.92M | $16.54M | $17.37M | $15.37M | $17.72M | $13.85M | $15.19M | $14.93M | $12.39M | $13.91M | $11.10M | $11.06M | $7.83M | $7.05M | $6.36M | $4.54M | $4.25M |
| Cost and Expenses | $11.62M | $12.64M | $18.40M | $24.06M | $16.62M | $17.37M | $15.37M | $17.72M | $13.85M | $15.19M | $14.93M | $12.39M | $13.91M | $11.10M | $11.06M | $7.83M | $7.05M | $6.36M | $4.54M | $4.25M |
| Interest Income | $435.00K | $576.00K | $855.00K | $1.09M | $1.34M | $1.19M | $897.00K | $1.07M | $933.00K | $60.00K | $34.00K | $14.00K | $21.00K | $26.00K | $26.00K | $29.00K | $32.00K | $29.00K | $5.00K | $16.00K |
| Interest Expense | $- | $- | $- | $- | $1.07M | $- | $- | $- | $12.00K | $- | $34.00K | $- | $257.00K | $- | $- | $- | $50.00K | $- | $- | $- |
| Depreciation and Amortization | $151.00K | $39.00K | $145.00K | $136.00K | $85.00K | $-68.00K | $-23.00K | $284.00K | $222.00K | $279.00K | $300.00K | $280.00K | $278.00K | $400.00K | $300.00K | $70.00K | $41.00K | $33.00K | $13.00K | $8.00K |
| EBITDA | $-9.62M | $-9.60M | $-17.66M | $-23.39M | $-16.39M | $-16.83M | $-14.91M | $-17.03M | $-13.62M | $-14.55M | $-14.11M | $-11.64M | $-13.36M | $-10.73M | $-10.76M | $-7.76M | $-7.01M | $-6.33M | $-4.53M | $-4.24M |
| EBITDA Ratio | -4600.48% | -4922.56% | -2953.18% | -4396.24% | -11227.40% | -3093.20% | -2908.08% | -4153.41% | -123790.91% | -4052.09% | -3496.81% | -125.69% | -4929.89% | -76650.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-11.41M | $-12.44M | $-48.97M | $-23.52M | $-16.48M | $-16.83M | $-16.50M | $-17.31M | $-15.15M | $-14.83M | $-14.52M | $-7.03M | $-13.64M | $-11.08M | $-11.06M | $-7.83M | $-7.05M | $-6.36M | $-4.54M | $-4.25M |
| Operating Income Ratio | -5458.37% | -6380.51% | -8189.63% | -4421.80% | -11285.62% | -3093.20% | -3603.28% | -4222.68% | -137772.73% | -4129.81% | -3567.08% | -130.91% | -5032.47% | -79150.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $435.00K | $576.00K | $855.00K | $1.09M | $1.34M | $1.19M | $897.00K | $1.07M | $933.00K | $60.00K | $34.00K | $14.00K | $21.00K | $26.00K | $26.00K | $29.00K | $32.00K | $29.00K | $5.00K | $16.00K |
| Income Before Tax | $-10.97M | $-11.87M | $-48.12M | $-22.44M | $-15.14M | $-15.63M | $-15.61M | $-16.24M | $-14.22M | $-14.77M | $-14.48M | $-7.01M | $-13.62M | $-11.05M | $-11.04M | $-7.80M | $-7.02M | $-6.33M | $-4.54M | $-4.23M |
| Income Before Tax Ratio | -5250.24% | -6085.13% | -8046.66% | -4217.67% | -10369.18% | -2874.08% | -3407.42% | -3961.22% | -129290.91% | -4113.09% | -3558.72% | -130.65% | -5024.72% | -78964.29% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $6.00K | $7.00K | $12.00K | $14.00K | $17.00K | $-16.00K | $12.00K | $14.00K | $13.00K | $- | $-68.00K | $-14.00K | $-278.00K | $-26.00K | $-26.00K | $-29.00K | $-32.00K | $-29.00K | $-5.00K | $-16.00K |
| Net Income | $-10.98M | $-11.87M | $-48.13M | $-22.45M | $-15.16M | $-15.65M | $-15.62M | $-16.25M | $-14.23M | $-14.77M | $-14.42M | $-7.00M | $-13.34M | $-11.05M | $-11.04M | $-7.80M | $-7.02M | $-6.33M | $-4.54M | $-4.23M |
| Net Income Ratio | -5253.11% | -6088.72% | -8048.66% | -4220.30% | -10380.82% | -2877.02% | -3410.04% | -3964.63% | -129409.09% | -4113.09% | -3542.01% | -130.39% | -4922.14% | -78964.29% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | $-0.18 | $-0.18 | $-0.74 | $-0.35 | $-0.26 | $-0.27 | $-0.36 | $-0.44 | $-0.45 | $-0.40 | $-0.42 | $-0.54 | $-1.03 | $-0.85 | $-0.85 | $-0.60 | $-0.57 | $-0.49 | $-0.55 | $-0.34 |
| EPS Diluted | $-0.18 | $-0.18 | $-0.74 | $-0.35 | $-0.26 | $-0.27 | $-0.36 | $-0.44 | $-0.45 | $-0.40 | $-0.42 | $-0.54 | $-1.03 | $-0.85 | $-0.85 | $-0.60 | $-0.57 | $-0.49 | $-0.55 | $-0.34 |
| Weighted Average Shares Outstanding | 65.46M | 65.46M | 65.46M | 64.01M | 57.21M | 56.95M | 43.68M | 36.83M | 31.83M | 36.83M | 33.95M | 13.01M | 12.97M | 13.00M | 12.99M | 12.95M | 12.40M | 12.92M | 8.18M | 12.38M |
| Weighted Average Shares Outstanding Diluted | 65.46M | 65.46M | 65.46M | 64.01M | 57.21M | 56.95M | 43.68M | 36.83M | 31.83M | 36.83M | 33.95M | 13.01M | 13.00M | 13.00M | 12.99M | 12.95M | 12.40M | 12.92M | 8.18M | 12.38M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $40.58M | $22.35M | $32.55M | $45.75M | $74.59M |
| Short Term Investments | $- | $80.40M | $65.34M | $- | $- |
| Cash and Short Term Investments | $40.58M | $102.75M | $97.89M | $45.75M | $74.59M |
| Net Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Other Current Assets | $2.45M | $2.07M | $2.94M | $4.34M | $2.65M |
| Total Current Assets | $43.02M | $104.82M | $100.83M | $47.92M | $75.92M |
| Property Plant Equipment Net | $21.33M | $35.28M | $4.47M | $5.86M | $4.47M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $1.39M | $329.00K | $329.00K |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $1.99M | $2.50M | $3.28M | $762.00K | $118.00K |
| Total Non-Current Assets | $23.32M | $37.78M | $9.14M | $6.95M | $4.91M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $66.35M | $142.60M | $109.97M | $54.87M | $80.83M |
| Account Payables | $1.18M | $3.13M | $2.62M | $3.12M | $922.00K |
| Short Term Debt | $4.12M | $8.91M | $3.51M | $2.15M | $1.97M |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $398.00K | $1.66M | $1.27M | $9.79M | $2.83M |
| Other Current Liabilities | $6.93M | $9.37M | $9.03M | $3.18M | $1.99M |
| Total Current Liabilities | $12.63M | $19.60M | $14.47M | $18.25M | $4.88M |
| Long Term Debt | $30.26M | $21.45M | $667.00K | $379.00K | $1.45M |
| Deferred Revenue Non-Current | $- | $12.14M | $14.08M | $1.93M | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $-14.08M | $-1.93M | $- |
| Other Non-Current Liabilities | $11.86M | $- | $- | $- | $- |
| Total Non-Current Liabilities | $42.12M | $33.58M | $14.74M | $2.31M | $1.45M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $54.75M | $53.18M | $29.21M | $20.55M | $6.34M |
| Preferred Stock | $- | $- | $- | $- | $80.83M |
| Common Stock | $65.00K | $57.00K | $32.00K | $13.00K | $13.00K |
| Retained Earnings | $-404.79M | $-311.36M | $-248.68M | $-193.40M | $-149.88M |
| Accumulated Other Comprehensive Income Loss | $- | $33.00K | $10.00K | $- | $-80.83M |
| Other Total Stockholders Equity | $416.32M | $400.69M | $329.39M | $227.70M | $305.19M |
| Total Stockholders Equity | $11.59M | $89.42M | $80.75M | $34.32M | $74.49M |
| Total Equity | $11.59M | $89.42M | $80.75M | $34.32M | $74.49M |
| Total Liabilities and Stockholders Equity | $66.35M | $142.60M | $109.97M | $54.87M | $80.83M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $66.35M | $142.60M | $109.97M | $54.87M | $80.83M |
| Total Investments | $- | $80.40M | $65.34M | $329.00K | $329.00K |
| Total Debt | $34.38M | $26.88M | $2.22M | $1.45M | $2.44M |
| Net Debt | $-6.20M | $4.53M | $-30.33M | $-44.29M | $-72.15M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $40.58M | $23.80M | $31.91M | $15.80M | $22.35M | $24.85M | $54.36M | $22.02M | $32.55M | $109.56M | $120.67M | $33.76M | $45.75M | $58.13M | $69.05M | $66.11M | $74.59M | $81.56M | $86.60M | $35.25M |
| Short Term Investments | $- | $27.83M | $35.59M | $71.32M | $80.40M | $77.70M | $61.79M | $60.69M | $65.34M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $40.58M | $51.63M | $67.50M | $87.12M | $102.75M | $102.55M | $116.15M | $82.71M | $97.89M | $109.56M | $120.67M | $33.76M | $45.75M | $58.13M | $69.05M | $66.11M | $74.59M | $81.56M | $86.60M | $35.25M |
| Net Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $5.00M | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Assets | $2.45M | $2.82M | $1.94M | $2.33M | $2.07M | $2.37M | $3.90M | $2.09M | $2.94M | $2.67M | $1.71M | $1.80M | $4.34M | $5.51M | $2.05M | $1.25M | $2.65M | $4.00M | $5.42M | $586.00K |
| Total Current Assets | $43.02M | $54.44M | $69.44M | $89.44M | $104.82M | $104.92M | $118.25M | $84.80M | $100.83M | $112.23M | $122.38M | $40.55M | $47.92M | $60.89M | $70.07M | $67.35M | $75.92M | $83.56M | $89.31M | $35.54M |
| Property Plant Equipment Net | $21.33M | $22.32M | $23.16M | $49.41M | $35.28M | $6.80M | $1.98M | $3.83M | $4.47M | $4.36M | $4.87M | $5.38M | $5.86M | $6.30M | $5.69M | $5.24M | $4.47M | $3.45M | $3.08M | $3.25M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $1.99M | $1.39M | $1.39M | $1.09M | $1.39M | $1.39M | $- | $1.09M | $329.00K | $329.00K | $329.00K | $329.00K | $329.00K | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $1.99M | $1.99M | $1.99M | $683.00K | $1.11M | $7.46M | $4.35M | $3.85M | $3.28M | $2.87M | $1.70M | $1.08M | $762.00K | $245.00K | $243.00K | $- | $447.00K | $329.00K | $329.00K | $1.98M |
| Total Non-Current Assets | $23.32M | $24.31M | $25.15M | $52.08M | $37.78M | $15.65M | $7.42M | $9.07M | $9.14M | $7.23M | $7.65M | $6.79M | $6.95M | $6.88M | $6.26M | $5.57M | $4.91M | $3.77M | $3.41M | $5.23M |
| Other Assets | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $66.35M | $78.76M | $94.58M | $141.53M | $142.60M | $120.58M | $125.67M | $93.87M | $109.97M | $119.46M | $130.03M | $47.34M | $54.87M | $67.76M | $76.33M | $72.92M | $80.83M | $87.33M | $92.72M | $40.77M |
| Account Payables | $1.18M | $2.29M | $4.97M | $2.84M | $3.13M | $5.05M | $4.19M | $3.95M | $2.62M | $2.90M | $1.67M | $2.41M | $3.12M | $2.91M | $1.90M | $1.17M | $922.00K | $530.00K | $1.15M | $1.36M |
| Short Term Debt | $4.12M | $4.00M | $8.54M | $4.50M | $10.87M | $2.81M | $3.38M | $3.80M | $3.51M | $1.31M | $1.85M | $2.19M | $1.07M | $2.10M | $1.03M | $1.01M | $985.00K | $1.93M | $1.89M | $1.84M |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $398.00K | $607.00K | $814.00K | $1.32M | $1.66M | $1.73M | $1.50M | $1.51M | $1.27M | $2.73M | $1.81M | $10.06M | $9.79M | $9.84M | $12.00M | $1.93M | $2.83M | $3.10M | $1.74M | $2.73M |
| Other Current Liabilities | $6.93M | $8.05M | $4.95M | $10.06M | $3.94M | $9.65M | $5.05M | $4.89M | $9.03M | $6.67M | $4.54M | $3.14M | $4.26M | $2.92M | $2.98M | $1.99M | $2.98M | $2.25M | $910.00K | $1.96M |
| Total Current Liabilities | $12.63M | $14.95M | $19.28M | $18.72M | $19.60M | $19.23M | $14.11M | $14.15M | $14.47M | $13.61M | $9.87M | $17.80M | $18.25M | $17.77M | $5.90M | $4.17M | $4.88M | $4.71M | $3.94M | $5.16M |
| Long Term Debt | $30.26M | $31.32M | $32.48M | $33.36M | $21.45M | $4.89M | $- | $191.00K | $667.00K | $3.00K | $3.00K | $99.00K | $379.00K | $656.00K | $929.00K | $1.20M | $1.45M | $1.71M | $1.96M | $2.19M |
| Deferred Revenue Non-Current | $11.86M | $11.86M | $11.85M | $11.94M | $12.14M | $12.21M | $12.99M | $13.43M | $14.08M | $12.63M | $9.13M | $1.29M | $1.93M | $2.15M | $12.00M | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $-11.94M | $-21.45M | $-12.21M | $- | $-13.43M | $-14.08M | $-12.63M | $-9.13M | $-2.02M | $-1.93M | $-2.15M | $-12.00M | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $160.20M |
| Total Non-Current Liabilities | $42.12M | $43.18M | $44.33M | $45.30M | $33.58M | $17.10M | $12.99M | $13.62M | $14.74M | $12.64M | $9.13M | $1.39M | $2.31M | $2.80M | $12.93M | $1.20M | $1.45M | $1.71M | $1.96M | $162.39M |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $54.75M | $58.14M | $63.60M | $64.02M | $53.18M | $36.34M | $27.10M | $27.78M | $29.21M | $26.24M | $19.00M | $19.19M | $20.55M | $20.57M | $18.83M | $5.37M | $6.34M | $6.42M | $5.90M | $167.55M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $0 | $- | $- | $- | $0 | $- | $0 | $87.33M | $92.72M | $39.74M |
| Common Stock | $65.00K | $65.00K | $65.00K | $61.00K | $57.00K | $50.00K | $50.00K | $32.00K | $32.00K | $32.00K | $32.00K | $13.00K | $13.00K | $13.00K | $13.00K | $13.00K | $13.00K | $13.00K | $13.00K | $- |
| Retained Earnings | $-404.79M | $-393.81M | $-381.94M | $-333.81M | $-311.36M | $-296.20M | $-280.55M | $-264.93M | $-248.68M | $-234.44M | $-214.89M | $-200.41M | $-193.40M | $-179.78M | $-168.72M | $-157.69M | $-149.88M | $-142.86M | $-136.53M | $-131.99M |
| Accumulated Other Comprehensive Income Loss | $- | $20.00K | $-4.00K | $25.00K | $33.00K | $-7.00K | $-27.00K | $-12.00K | $10.00K | $- | $-0 | $- | $- | $- | $-0 | $0 | $-0 | $-87.33M | $-2.85M | $-2.84M |
| Other Total Stockholders Equity | $416.32M | $414.35M | $412.85M | $411.23M | $400.69M | $380.39M | $379.10M | $331.00M | $329.39M | $327.63M | $325.89M | $228.55M | $227.70M | $226.96M | $226.21M | $225.22M | $224.36M | $223.76M | $223.34M | $-34.53M |
| Total Stockholders Equity | $11.59M | $20.62M | $30.98M | $77.50M | $89.42M | $84.24M | $98.58M | $66.09M | $80.75M | $93.22M | $111.03M | $28.16M | $34.32M | $47.19M | $57.50M | $67.55M | $74.49M | $80.91M | $86.82M | $-126.78M |
| Total Equity | $11.59M | $20.62M | $30.98M | $77.50M | $89.42M | $84.24M | $98.58M | $66.09M | $80.75M | $93.22M | $111.03M | $28.16M | $34.32M | $47.19M | $57.50M | $67.55M | $74.49M | $80.91M | $86.82M | $-126.78M |
| Total Liabilities and Stockholders Equity | $66.35M | $78.76M | $94.58M | $141.53M | $142.60M | $120.58M | $125.67M | $93.87M | $109.97M | $119.46M | $130.03M | $47.34M | $54.87M | $67.76M | $76.33M | $72.92M | $80.83M | $87.33M | $92.72M | $40.77M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $66.35M | $78.76M | $94.58M | $141.53M | $142.60M | $120.58M | $125.67M | $93.87M | $109.97M | $119.46M | $130.03M | $47.34M | $54.87M | $67.76M | $76.33M | $72.92M | $80.83M | $87.33M | $92.72M | $40.77M |
| Total Investments | $- | $27.83M | $35.59M | $73.31M | $81.79M | $77.70M | $61.79M | $60.69M | $65.34M | $- | $1.09M | $329.00K | $329.00K | $329.00K | $329.00K | $329.00K | $- | $- | $- | $- |
| Total Debt | $34.38M | $35.32M | $36.75M | $37.86M | $26.88M | $6.29M | $1.69M | $2.09M | $2.22M | $657.00K | $929.00K | $1.20M | $1.45M | $1.71M | $1.96M | $2.20M | $2.44M | $2.67M | $2.90M | $3.11M |
| Net Debt | $-6.20M | $11.52M | $4.84M | $22.06M | $4.53M | $-18.56M | $-52.67M | $-19.93M | $-30.33M | $-108.90M | $-119.74M | $-32.56M | $-44.29M | $-56.42M | $-67.09M | $-63.90M | $-72.15M | $-78.88M | $-83.70M | $-32.14M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-93.44M | $-62.68M | $-55.28M | $-43.51M | $-22.13M |
| Depreciation and Amortization | $471.00K | $278.00K | $1.07M | $1.00M | $95.00K |
| Deferred Income Tax | $- | $- | $- | $-2.42M | $- |
| Stock Based Compensation | $6.72M | $5.89M | $5.45M | $2.77M | $1.81M |
| Change in Working Capital | $-6.35M | $-4.88M | $4.55M | $13.92M | $-879.00K |
| Accounts Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Accounts Payables | $-1.89M | $450.00K | $-2.41M | $2.35M | $345.00K |
| Other Working Capital | $-4.46M | $-5.33M | $6.97M | $11.57M | $-1.22M |
| Other Non Cash Items | $22.58M | $-1.90M | $824.00K | $2.42M | $-45.00K |
| Net Cash Provided by Operating Activities | $-70.01M | $-63.30M | $-43.38M | $-25.82M | $-21.14M |
| Investments in Property Plant and Equipment | $-2.34M | $-1.05M | $-164.00K | $-3.38M | $-1.77M |
| Acquisitions Net | $- | $- | $- | $- | $- |
| Purchases of Investments | $-47.95M | $-122.42M | $-64.84M | $- | $- |
| Sales Maturities of Investments | $130.59M | $110.89M | $- | $- | $- |
| Other Investing Activities | $- | $-1 | $-64.84M | $- | $- |
| Net Cash Used for Investing Activities | $80.31M | $-12.58M | $-65.01M | $-3.38M | $-1.77M |
| Debt Repayment | $- | $- | $- | $- | $- |
| Common Stock Issued | $8.82M | $69.24M | $100.50M | $604.00K | $59.89M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $-287.00K | $-3.55M | $-4.24M | $359.00K | $27.81M |
| Net Cash Used Provided by Financing Activities | $8.53M | $65.69M | $96.26M | $359.00K | $87.70M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $18.82M | $-10.20M | $-12.13M | $-28.85M | $64.78M |
| Cash at End of Period | $42.57M | $23.75M | $33.94M | $46.08M | $74.92M |
| Cash at Beginning of Period | $23.75M | $33.94M | $46.08M | $74.92M | $10.14M |
| Operating Cash Flow | $-70.01M | $-63.30M | $-43.38M | $-25.82M | $-21.14M |
| Capital Expenditure | $-2.34M | $-1.05M | $-164.00K | $-3.38M | $-1.77M |
| Free Cash Flow | $-72.35M | $-64.35M | $-43.55M | $-29.20M | $-22.92M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-10.98M | $-11.87M | $-48.13M | $-22.45M | $-15.16M | $-15.65M | $-15.62M | $-16.25M | $-14.23M | $-19.55M | $-14.48M | $-7.01M | $-13.62M | $-11.05M | $-11.04M | $-7.80M | $-7.02M | $-6.33M | $-4.54M | $-4.23M |
| Depreciation and Amortization | $151.00K | $-1.97M | $145.00K | $136.00K | $85.00K | $-68.00K | $-23.00K | $284.00K | $222.00K | $279.00K | $286.00K | $280.00K | $278.00K | $350.00K | $303.00K | $70.00K | $41.00K | $33.00K | $13.00K | $8.00K |
| Deferred Income Tax | $- | $- | $- | $- | $-5.19M | $- | $- | $- | $- | $- | $-2.67M | $- | $-13.92M | $- | $- | $- | $879.00K | $- | $- | $- |
| Stock Based Compensation | $1.94M | $1.49M | $1.12M | $2.16M | $1.48M | $1.44M | $1.35M | $1.61M | $1.76M | $1.74M | $1.11M | $844.00K | $782.00K | $733.00K | $656.00K | $599.00K | $592.00K | $468.00K | $619.00K | $134.00K |
| Change in Working Capital | $-2.20M | $-1.33M | $2.70M | $-1.37M | $-4.38M | $1.22M | $-961.00K | $-763.00K | $-732.00K | $6.68M | $4.62M | $-6.02M | $1.26M | $-342.00K | $13.46M | $-457.00K | $520.00K | $2.10M | $-3.57M | $73.00K |
| Accounts Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $5.00M | $- | $5.00M | $-5.00M | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-5.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $-1.11M | $-2.59M | $2.38M | $-560.00K | $-3.54M | $796.00K | $-106.00K | $3.29M | $-2.24M | $1.47M | $-976.00K | $-663.00K | $1.18M | $424.00K | $291.00K | $452.00K | $204.00K | $3.00K | $-294.00K | $432.00K |
| Other Working Capital | $-1.08M | $1.26M | $319.00K | $-808.00K | $-846.00K | $424.00K | $-855.00K | $-4.06M | $-3.49M | $4.42M | $5.60M | $-354.00K | $77.00K | $-766.00K | $13.17M | $-909.00K | $316.00K | $2.10M | $-3.28M | $-359.00K |
| Other Non Cash Items | $-267.00K | $-2.54M | $24.18M | $2.06M | $4.10M | $-1.06M | $966.00K | $-726.00K | $824.00K | $1.11M | $2.67M | $7.07M | $13.92M | $1.06M | $968.00K | $287.00K | $-879.00K | $-45.00K | $-294.00K | $432.00K |
| Net Cash Provided by Operating Activities | $-11.35M | $-16.22M | $-19.98M | $-22.45M | $-19.06M | $-14.11M | $-14.28M | $-15.85M | $-12.16M | $-10.85M | $-8.47M | $-11.90M | $-11.30M | $-10.31M | $3.38M | $-7.59M | $-5.87M | $-3.78M | $-7.48M | $-4.02M |
| Investments in Property Plant and Equipment | $58.00K | $-51.00K | $-196.00K | $-2.15M | $-787.00K | $-144.00K | $-71.00K | $-45.00K | $-28.00K | $-29.00K | $-14.00K | $-93.00K | $-1.08M | $-517.00K | $-625.00K | $-1.16M | $-1.10M | $-589.00K | $-77.00K | $-8.00K |
| Acquisitions Net | $- | $- | $- | $- | $-9.96M | $14.84M | $490.00K | $-5.36M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $-12.81M | $-14.62M | $-20.52M | $-49.66M | $-42.84M | $-25.49M | $-4.44M | $-64.84M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $28.07M | $21.00M | $50.99M | $30.53M | $48.09M | $28.00M | $25.00M | $9.80M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $- | $- | $10.01M | $-1.57M | $-14.84M | $-490.00K | $5.36M | $-64.84M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Cash Used for Investing Activities | $28.13M | $8.14M | $36.18M | $7.86M | $-2.36M | $-14.98M | $-561.00K | $5.32M | $-64.87M | $-29.00K | $-14.00K | $-93.00K | $-1.08M | $-517.00K | $-625.00K | $-1.16M | $-1.10M | $-589.00K | $-77.00K | $-8.00K |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $-1.00K | $-3.00K | $9.00K | $8.81M | $19.24M | $2.00K | $50.10M | $4.00K | $100.50M | $- | $- | $8.00K | $604.00K | $11.00K | $331.00K | $262.00K | $30.39M | $- | $- | $30.39M |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $- | $-23.00K | $-89.00K | $8.64M | $-322.00K | $-418.00K | $47.19M | $4.00K | $-196.99M | $-236.00K | $96.49M | $6.00K | $-4.00K | $-84.00K | $185.00K | $262.00K | $7.00K | $-675.00K | $58.91M | $29.46M |
| Net Cash Used Provided by Financing Activities | $-1.00K | $-23.00K | $-89.00K | $8.64M | $18.92M | $-418.00K | $47.19M | $4.00K | $-96.49M | $-236.00K | $96.49M | $6.00K | $-4.00K | $-84.00K | $185.00K | $262.00K | $7.00K | $-675.00K | $58.91M | $29.46M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- | $- | $- | $- | $96.49M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $16.78M | $-8.11M | $16.11M | $-6.55M | $-2.50M | $-29.51M | $32.34M | $-10.53M | $-77.03M | $-11.11M | $88.00M | $-11.99M | $-12.38M | $-10.91M | $2.94M | $-8.49M | $-6.96M | $-5.04M | $51.35M | $25.44M |
| Cash at End of Period | $42.57M | $25.79M | $31.91M | $15.80M | $22.35M | $26.24M | $55.75M | $23.41M | $33.94M | $110.98M | $122.09M | $34.08M | $46.08M | $58.46M | $69.38M | $66.43M | $74.92M | $81.88M | $86.93M | $35.58M |
| Cash at Beginning of Period | $25.79M | $33.90M | $15.80M | $22.35M | $24.85M | $55.75M | $23.41M | $33.94M | $110.98M | $122.09M | $34.08M | $46.08M | $58.46M | $69.38M | $66.43M | $74.92M | $81.88M | $86.93M | $35.58M | $10.14M |
| Operating Cash Flow | $-11.35M | $-16.22M | $-19.98M | $-22.45M | $-19.06M | $-14.11M | $-14.28M | $-15.85M | $-12.16M | $-10.85M | $-8.47M | $-11.90M | $-11.30M | $-10.31M | $3.38M | $-7.59M | $-5.87M | $-3.78M | $-7.48M | $-4.02M |
| Capital Expenditure | $58.00K | $-51.00K | $-196.00K | $-2.15M | $-787.00K | $-144.00K | $-71.00K | $-45.00K | $-28.00K | $-29.00K | $-14.00K | $-93.00K | $-1.08M | $-517.00K | $-625.00K | $-1.16M | $-1.10M | $-589.00K | $-77.00K | $-8.00K |
| Free Cash Flow | $-11.29M | $-16.27M | $-20.18M | $-24.60M | $-19.84M | $-14.26M | $-14.35M | $-15.89M | $-12.19M | $-10.88M | $-8.48M | $-12.00M | $-12.38M | $-10.83M | $2.76M | $-8.75M | $-6.97M | $-4.37M | $-7.55M | $-4.03M |
Lyra Therapeutics Dividends
Explore Lyra Therapeutics's dividend history, including dividend yield, payout ratio, and historical payments.
Lyra Therapeutics News
Read the latest news about Lyra Therapeutics, including recent articles, headlines, and updates.
Lyra Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
WATERTOWN, Mass., March 13, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis (CRS), today reported its financial results for the fourth quarter and full year ended December 31, 2024 and provided a corporate update.
Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
WATERTOWN, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis (CRS), today reported its financial results for the third quarter ended September 30, 2024 and provided a corporate update.
Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis
-- Topline Results Expected Q2 2025 -- WATERTOWN, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting anti-inflammatory therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced that the pivotal Phase 3 ENLIGHTEN 2 clinical trial of LYR-210 in adult patients with CRS who have not had prior ethmoid sinus surgery, is fully enrolled. LYR-210 is a bioresorbable nasal implant designed to deliver six months of continuous anti-inflammatory medication (mometasone furoate) to the sinonasal passages for the treatment of CRS. Topline results from ENLIGHTEN 2 are expected in Q2 2025.
Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings
WATERTOWN, Mass., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting anti-inflammatory therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced that the Company will present results from the Phase 3 ENLIGHTEN 1 study for LYR-210, the company's lead product candidate for CRS, at the 70th Annual Meeting of the American Rhinologic Society (ARS), taking place September 27-28 in Miami. The Company will also present additional results from the Phase 2 BEACON study for LYR-220 in adult patients with CRS who have had prior ethmoid sinus surgery at the Annual Meeting of the American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS), taking place September 28 - October 1 in Miami.
Lyra Therapeutics Announces Cost-Cutting Measures to Preserve Capital
WATERTOWN, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), today announced that it is advancing its goal to preserve capital by implementing a layoff of approximately 75% of its workforce, in addition to other cost-cutting measures.
Why Is Lyra Therapeutics (LYRA) Stock Down 90% Today?
Lyra Therapeutics (NASDAQ: LYRA ) stock is falling hard on Monday after the clinical-stage biotechnology company announced results from a Phase 3 clinical trial of LYR-210. LYR-210 is the company's potential treatment for chronic rhinosinusitis currently in development.
Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis
ENLIGHTEN 1 trial did not meet its primary endpoint Company plans to evaluate full dataset and path forward WATERTOWN, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), today announced topline results from the Company's Phase 3 ENLIGHTEN 1 trial evaluating LYR-210 for the treatment of chronic rhinosinusitis (CRS).
Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
-- Phase 3 Results from ENLIGHTEN 1 Trial of LYR-210 in Chronic Rhinosinusitis (CRS) Expected in May -- -- Phase 3 Results from ENLIGHTEN 1 Trial of LYR-210 in Chronic Rhinosinusitis (CRS) Expected in May --
Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WATERTOWN, Mass., April 26, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (the “Company” or “Lyra”), a clinical-stage biotech developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis (CRS), today announced that it has granted non-qualified stock options to purchase a total of 78,400 shares of Lyra Therapeutics common stock to 16 new non-executive employees as an inducement material to their acceptance of employment with Lyra Therapeutics. The employment inducement awards were approved by Lyra's independent directors serving on its Compensation Committee and granted under Lyra's 2022 Employment Inducement Award Plan, as amended, and related form of stock option agreement in accordance with Nasdaq Listing Rule 5635(c)(4).
Lyra Therapeutics (LYRA) Is a Great Choice for 'Trend' Investors, Here's Why
Lyra Therapeutics (LYRA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Wall Street Analysts See a 101.81% Upside in Lyra Therapeutics (LYRA): Can the Stock Really Move This High?
The consensus price target hints at a 101.8% upside potential for Lyra Therapeutics (LYRA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
-- Data from ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Chronic Rhinosinusitis (CRS) Anticipated Q2 2024 -- WATERTOWN, Mass., March 21, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory nasal inserts for the treatment of chronic rhinosinusitis (CRS), today reported its financial results for the fourth quarter and full year ended December 31, 2023 and provided a corporate update.
Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WATERTOWN, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory nasal inserts for the treatment of chronic rhinosinusitis (CRS), today announced that it has granted non-qualified stock options to purchase a total of 119,200 shares of Lyra common stock to 18 new non-executive employees as an inducement material to their acceptance of employment with Lyra. The employment inducement awards were approved by Lyra's independent directors serving on its Compensation Committee and granted under the Company's 2022 Inducement Award Plan, as amended, and related form of stock option agreement in accordance with Nasdaq Listing Rule 5635(c)(4).
Strength Seen in Lyra Therapeutics, Inc. (LYRA): Can Its 6.9% Jump Turn into More Strength?
Lyra Therapeutics, Inc. (LYRA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Lyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
– Additional Phase 2 BEACON trial CT scan data demonstrated statistically significant improvement in sinus opacification with LYR-220 and provided radiological evidence of improvement in chronic rhinosinusitis (CRS) patients who have had prior ethmoid sinus surgery –
Lyra Therapeutics to Participate in Upcoming Investor Conferences
WATERTOWN, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced that Maria Palasis, Ph.D., President and Chief Executive Officer, will participate in the following investor conferences in November:
Lyra Therapeutics Announces Appointment of Ronan O'Brien as Chief Legal Officer
WATERTOWN, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (“CRS”), today announced the appointment of Ronan O'Brien, as Chief Legal Officer, effective October 16, 2023.
Lyra Therapeutics: Hold For Phase 3 Topline
Lyra Therapeutics has two product candidates in clinical trials for Chronic rhinosinusitis (CRS) patients. Both candidates, LYR-210 and LYR-220, show promising efficacy data, with LYR-210 in phase 3 trials and LYR-220 in phase 2 trials. Lyra has a market cap of $190mn and enough cash to sustain operations until 2025, but more cash would be desirable.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for LYRA.